ERNST RENONDEAU: Open Payments
NPI 1134714546 · EDISON, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,041 in 135 payments from 9 companies in 2025. Trend: 2023 $2,037 · 2024 $2,149 · 2025 $2,041
Food & beverage: $2,041
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 56 | $661 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $356 |
| Alkermes, Inc. | 13 | $324 |
| E.R. Squibb & Sons, L.L.C. | 13 | $198 |
| ABBVIE INC. | 22 | $197 |
| Neurocrine BioSciences, Inc. | 8 | $145 |
| Otsuka America Pharmaceutical, Inc. | 3 | $69 |
| Janssen Pharmaceuticals, Inc | 3 | $57 |
| Indivior Inc. | 2 | $34 |
Products named: AUSTEDO XR, CAPLYTA, ARISTADA, UZEDY, COBENFY, VRAYLAR, INGREZZA, REXULTI.
Industry payments across NJ — which companies pay providers there.
